Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
Phase 1
Completed
- Conditions
- Actinic Keratosis
- Interventions
- Drug: LEO 43204 gel 0.018%Drug: LEO 43204 gel 0.1%Drug: LEO 43204 gel 0.037%
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT02424305
- Locations
- 🇺🇸
Pflugerville Dermatology Clinical Research, Pflugerville, Texas, United States
PMS to Evaluate the Safety and Efficacy of Picato® Gel
Completed
- Conditions
- Actinic Keratosis
- Interventions
- Drug: Ingenol mebutate 0.015 percent or 0.05 percent gel
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1324
- Registration Number
- NCT02421471
- Locations
- 🇰🇷
Department of Dermatology, Korea University Anam Hospital, Seoul, Korea, Republic of
A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)
Phase 2
Completed
- Conditions
- Skin and Connective Tissue Diseases
- Interventions
- Drug: Aerosol spray vehicleDrug: LP0113 aerosol sprayDrug: LEO 90100 aerosol foamDrug: Daivobet® gel
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT02416258
- Locations
- 🇫🇷
Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Nice, France
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
Phase 4
Completed
- Conditions
- Actinic Keratosis (AK)
- Interventions
- Drug: Ingenol Mebutate Gel, 0.015%
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 502
- Registration Number
- NCT02406014
- Locations
- 🇩🇪
Gemain, Weber & Craninic, Schweinfurt, Germany
A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin
Phase 1
Completed
- Conditions
- Skin Tissue DiseasesConnective Tissue Diseases
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT02392130
- Locations
- 🇩🇪
bioskin GmbH, Hamburg, Germany
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 117
- Registration Number
- NCT02387853
- Locations
- 🇵🇱
MULTIKLINIKA SALUTE Sp zo.o., Katowice, Poland
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸Redwood Family Dermatology, Santa Rosa, California, United States
Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Skin and Connective Tissue Diseases
- Interventions
- Drug: LEO 80185 gel, vehicle, liquid paraffin
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 33
- Registration Number
- NCT02379793
- Locations
- 🇯🇵
Medical Co. LTA HAKATA Clinic, Random Square 5F, 6-18 Tenyamachi, Hakata-ku, Fukuoka, Japan
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
Phase 2
Completed
- Conditions
- Anogenital Warts
- Interventions
- Drug: Picato
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT02377999
- Locations
- 🇩🇰
Bispebjerg Hospital, Copenhagen NV, Denmark
A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Glaxal Base cream vehicle
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT02376049
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
🇮🇱Beit Harofim, Netanya, Israel
The Real Life Topical Field Treatment of Actinic Keratosis Study
Completed
- Conditions
- Actinic Keratosis
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1168
- Registration Number
- NCT02362152
- Locations
- 🇳🇱
Lievensberg Ziekenhuis, Bergen op Zoom, Netherlands
© Copyright 2025. All Rights Reserved by MedPath